Teladoc Health, Inc. (TDOC) Q2 2025 Earnings Call Transcript

Teladoc Health reported a strong Q2 2025, with consolidated revenue of $631.9 million and adjusted EBITDA of $69.3 million both at the high end of guidance, primarily driven by robust 3.7% growth in its Integrated Care segment. While Integrated Care's performance led to a slight upward revision in the full-year revenue outlook, the BetterHelp segment continues to face significant headwinds in its U.S. cash-pay business, making its methodical transition to insurance-based services, which is showing encouraging early signs but meaningful revenue contribution is not expected until 2026, critical for its future growth. The company is focused on disciplined execution, strategic product innovation, and cost management to return to overall growth, despite a slight downward revision to full-year adjusted EBITDA guidance partly due to tariff impacts.

Analysis

Teladoc Health reported mixed Q2 2025 results, characterized by a significant divergence between its two primary segments. The company exceeded the high end of its guidance for both consolidated revenue ($631.9 million) and adjusted EBITDA ($69.3 million), but this was driven almost entirely by the outperformance of its Integrated Care division. This segment grew revenue by 3.7% year-over-year to $391.5 million, supported by an 11% increase in U.S. members to 102.4 million and a mid-teens growth rate in its international business. Consequently, full-year revenue guidance for Integrated Care was raised. In stark contrast, the BetterHelp segment continues to face material headwinds in its core U.S. cash-pay business, with paying users declining 5% year-over-year to 388,000 due to higher churn and customer acquisition costs. Management attributes this weakness to a broader consumer shift towards insurance-covered therapy, validating their strategic pivot. The recently acquired UpLift is central to this transition, with a soft launch of insurance acceptance now underway in one state. While this initiative is deemed "essential" for BetterHelp's long-term stability and growth, a meaningful revenue contribution is not anticipated until 2026, and the company no longer expects BetterHelp to achieve flat year-over-year growth in Q4 2025. The full-year consolidated adjusted EBITDA guidance was revised slightly downward to a midpoint of $278.5 million, reflecting the BetterHelp weakness and a new $3 million headwind from tariffs.

Key Decisions for Investors

• Investors should closely monitor the BetterHelp insurance initiative's progress, including user conversion, therapist network growth, and payer expansion, as its success is now critical to offsetting the secular decline in the U.S. cash-pay business and returning the segment to growth in 2026.
• It is prudent to evaluate the robust, guidance-raising Integrated Care segment separately from the challenged BetterHelp segment to accurately assess risk, as the company's overall performance is currently a tale of two distinct businesses.
• Despite the lowered full-year EBITDA outlook, the strong balance sheet with 1.1x net leverage provides a buffer during this transition; focus on management commentary regarding the margin profile of the new insurance model, as this will be a key determinant of long-term profitability.
• Given the ongoing weakness in BetterHelp's cash-pay model, consider the potential for continued reallocation of marketing spend to more efficient international markets or the Integrated Care segment to support near-term profitability.